Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: software salesperson who wrote (5771)	3/8/2002 1:03:14 AM
From: aknahow	Respond to of 52153

<<<1. while it is certainly possible that one of the new biologics will be found to be efficacious against PA, i don't recall seeing any info from either bgen or dna/xoma along those lines.>>> DNA/XOMA will "shortly" begin clinical trial of Xanelim for RA. Recent conference call said that results of subjects treated with Xanelim for psoriasis were one of the factors that led to the choice of the RA indication. RA is not PA but perhaps more information will be released when the trials actually start.